ALG-010133

N/A

Report date: 2023/05/30 20:00:25
NME

Base Information

Drug NameALG-010133
Drug Alias NameALG-010133
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide
Mechanisms of ActionHBsAg inhibitors
TargetsHepatitis B Surface Antigens
Therapy Area/IndicationsHepatitis B, ChronicHepatitis B
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNew ZealandAustralia +[8] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesAligos Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesAligos Therapeutics Inc
Inactive CompaniesDmed Biopharmaceutical Co LtdDalton Pharma Services
Active IndicationsHepatitis B, Chronic
Inactive IndicationsHepatitis B

Other Information

ATC CodeN/A
Related LinksN/A